irbesartan + amlodipine + carvedilol

A combination drug containing **irbesartan**, **amlodipine**, and **carvedilol**—each with established antihypertensive effects but, to current knowledge, not co-formulated as a single, approved product. - **Irbesartan** is an angiotensin II receptor blocker (ARB) that antagonizes the angiotensin II type 1 receptor on vascular smooth muscle, leading to vasodilation, blood pressure reduction, and renal protection in some patients. - **Amlodipine** is a dihydropyridine calcium channel blocker (CCB) that inhibits L-type calcium channels in vascular smooth muscle, causing peripheral vasodilation and reduced blood pressure[1][2][3]. - **Carvedilol** is a non-selective beta-adrenergic blocker with additional alpha-1 blocking activity, leading to decreased heart rate, contractility, and further vasodilation. This triple mechanism targets several pathways in hypertension and cardiovascular risk management, potentially providing enhanced blood pressure control in patients requiring multiple agents. Irbesartan + amlodipine fixed-dose combinations (FDCs) are marketed and studied for hypertension as single-pill options, but fixed-dose triple combinations with carvedilol do not appear to be available on the market or in clinical trials, thus such a combination would typically involve concomitant administration of individual agents[1][2][3].